GlassScriptPhysician profile
Benjamin Zenger
NPI 1861073728
$495.80
in general payments reported to CMS, 2019-2025
12 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $86.22 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $107.87 | 2024-2025 | Korlym |
| Abbvie INC. | $87.15 | 2025 | |
| Xeris Pharmaceuticals, INC. | $64.91 | 2025 | Gvoke Hypopen |
| Janssen Biotech, INC. | $49.59 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $48.73 | 2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.17 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $30.84 | 2024-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $16.26 | 2024 | Fanapt |
| Lilly USA, LLC | $14.42 | 2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.20 | 2025 | Caplyta |
| Pfizer INC. | $14.11 | 2025 | |
| Axsome Therapeutics, INC. | $8.55 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Zenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.